,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-10-18 00:13:00,The Zacks Research Daily presents the best research output of our analyst team.,0.6325156092643738,0.012341027148067951,0.35514333844184875,positive,0.6201745867729187
1,2017-10-18 00:13:00,"Today's Research Daily features new research reports on 12 major stocks, including IBM Corp (IBM), Celgene (CELG) and Procter & Gamble (PG).",0.04081623628735542,0.0081933056935668,0.9509904980659485,neutral,0.03262292966246605
2,2017-10-18 00:13:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
3,2017-10-18 00:13:00,"You can see all of today's research reports here >>>

IBM Corp 's shares have underperformed the broader market on a year to date basis, losing -9.2% vs. the S&P 500's +16.4% gain.",0.025571634992957115,0.9639589786529541,0.01046936959028244,negative,-0.9383873343467712
4,2017-10-18 00:13:00,IBM's third-quarter results benefited from higher cognitive solutions and systems revenues.,0.9470434784889221,0.021206192672252655,0.03175025060772896,positive,0.9258372783660889
5,2017-10-18 00:13:00,"Cognitive revenues grew on strong demand for security, IoT and analytics offerings.",0.9336177706718445,0.013990090228617191,0.05239207670092583,positive,0.9196276664733887
6,2017-10-18 00:13:00,The new z14 mainframe product drove systems revenues.,0.8830468654632568,0.014782540500164032,0.1021706610918045,positive,0.8682643175125122
7,2017-10-18 00:13:00,"IBM expects strong revenue growth in the fourth quarter on a sequential basis, driven by an anticipated solid demand for the z14 mainframe.",0.9495899081230164,0.014124135486781597,0.03628592565655708,positive,0.9354657530784607
8,2017-10-18 00:13:00,"The Zacks analyst likes the company's continuing strength in cloud, mobile, security and analytics as well as its cost savings actions and expects these factors to drive profitability.",0.9385592341423035,0.01318126916885376,0.048259437084198,positive,0.9253779649734497
9,2017-10-18 00:13:00,The company's expanding footprint in the rapidly growing blockchain market is another positive.,0.9018603563308716,0.01283871941268444,0.08530091494321823,positive,0.889021635055542
10,2017-10-18 00:13:00,Continuing share buyback and dividend payout are major attractions for investors.,0.35123562812805176,0.011404206976294518,0.637360155582428,neutral,0.3398314118385315
11,2017-10-18 00:13:00,"However, intensifying competition in most of the markets is a major concern.",0.026705482974648476,0.03261898085474968,0.9406755566596985,neutral,-0.005913497880101204
12,2017-10-18 00:13:00,(You can read the full research report on IBM Corp here >>> ) .,0.013818198814988136,0.01397415716201067,0.9722076058387756,neutral,-0.00015595834702253342
13,2017-10-18 00:13:00,"Shares of Celgene have outperformed the Zacks Biomedical and Genetics industry in the year so far, gaining +20% vs. +14.7%.",0.8253434896469116,0.15316669642925262,0.02148985117673874,positive,0.6721767783164978
14,2017-10-18 00:13:00,Celgene's Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration.,0.9526842832565308,0.02675139531493187,0.020564362406730652,positive,0.9259328842163086
15,2017-10-18 00:13:00,"Other key products - Pomalyst/Imnovid, Abraxane and Otezla - also performed well.",0.9412353038787842,0.019185593351721764,0.03957904502749443,positive,0.9220497012138367
16,2017-10-18 00:13:00,The consecutive increase in annual earnings guidance is also a positive.,0.9392955303192139,0.01631433144211769,0.04439013823866844,positive,0.9229812026023865
17,2017-10-18 00:13:00,Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018.,0.8803015351295471,0.011543255299329758,0.10815531760454178,positive,0.8687582612037659
18,2017-10-18 00:13:00,The approval of Idhifa in the U.S. for relapsed and/or refractory acute myeloid leukemia has further boosted the company's portfolio.,0.9520062804222107,0.016323674470186234,0.03167008236050606,positive,0.9356825947761536
19,2017-10-18 00:13:00,"However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue while Abraxane sales are under competitive pressure.",0.06080985441803932,0.7455682754516602,0.19362176954746246,negative,-0.6847584247589111
20,2017-10-18 00:13:00,(You can read the full research report on Celgene here >>> ) .,0.013327891938388348,0.011790039017796516,0.9748821258544922,neutral,0.0015378529205918312
21,2017-10-18 00:13:00,Procter & Gamble 's shares have underperformed the Zacks Soap and Cleaning Materials industry so far this year (+13% vs. +23.5%).,0.14465467631816864,0.8303795456886292,0.024965837597846985,negative,-0.6857248544692993
22,2017-10-18 00:13:00,"But the Zacks analyst likes the company's strong brand recognition, diversified portfolio, impressive product development capabilities and marketing prowess as well as strong cash flow productivity.",0.8708025217056274,0.01366287749260664,0.11553465574979782,positive,0.8571396470069885
23,2017-10-18 00:13:00,The company is investing in its brands and products as well as redesigning the supply chain to improve productivity and organic growth.,0.8364386558532715,0.0114588038995862,0.15210258960723877,positive,0.824979841709137
24,2017-10-18 00:13:00,"However, slowing market growth, weak volumes and major foreign exchange headwinds have been hurting sales.",0.022122209891676903,0.9665842652320862,0.011293560266494751,negative,-0.9444620609283447
25,2017-10-18 00:13:00,Soft consumer-spending environment in developed markets and uncertainties in emerging countries also add to the worries.,0.09388434886932373,0.5690229535102844,0.33709272742271423,negative,-0.4751386046409607
26,2017-10-18 00:13:00,"That said, P&G is speeding up innovations and investments to counter the softening industry growth.",0.8501840829849243,0.012819827534258366,0.13699613511562347,positive,0.8373642563819885
27,2017-10-18 00:13:00,Its productivity improvements and cost-saving efforts are also consistently helping to boost profit level.,0.9573743343353271,0.018996182829141617,0.023629505187273026,positive,0.9383781552314758
28,2017-10-18 00:13:00,(You can read the full research report on Intel here >>> ) .,0.014734398573637009,0.013562409207224846,0.9717032313346863,neutral,0.0011719893664121628
29,2017-10-18 00:13:00,"Other noteworthy reports we are featuring today include Valero (VLO), Gilead (GILD) and Sprint (S).",0.04650377482175827,0.005420735105872154,0.9480754733085632,neutral,0.04108303785324097
30,2017-10-18 00:13:00,"The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues.",0.8233587145805359,0.015582907944917679,0.16105839610099792,positive,0.8077757954597473
31,2017-10-18 00:13:00,"By 2020, it's predicted to blast through the roof to $47 billion.",0.23545314371585846,0.11051791906356812,0.6540289521217346,neutral,0.12493522465229034
32,2017-10-18 00:13:00,"Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.",0.7029615044593811,0.025822270661592484,0.2712162435054779,positive,0.6771392226219177
33,2017-10-18 00:13:00,"See Zacks' 3 Best Stocks to Play This Trend >>

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings.",0.13210587203502655,0.008039882406592369,0.8598542213439941,neutral,0.12406598776578903
34,2017-10-18 00:13:00,He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports.,0.026142945513129234,0.011532393284142017,0.9623246192932129,neutral,0.014610552228987217
35,2017-10-18 00:13:00,"If you want an email notification each time Sheraz publishes a new article, please click here>>>

The Zacks analyst is bullish about Sprint's efforts to fortify itself in the wireless industry with its network modernization efforts, attractive unlimited data plans amid high debt levels.",0.9066202640533447,0.019835595041513443,0.07354416698217392,positive,0.8867846727371216
36,2017-10-18 00:13:00,"While appreciating Williams Companies' healthy dividend coverage and steady payouts, the Zacks analyst remains concerned over the energy infrastructure provider's high debt-to-equity ratio.",0.06788191199302673,0.8924332857131958,0.03968480974435806,negative,-0.8245513439178467
37,2017-10-18 00:13:00,"Per the Zacks analyst, higher organic growth drove Omnicom's Q3 earnings beat although risks related to Brexit continue to impair its ability to increase revenues.",0.9330211281776428,0.0474027618765831,0.019576147198677063,positive,0.8856183886528015
38,2017-10-18 00:13:00,"Per the analyst, improving premiums will continue to boost Reinsurance Group's earnings, resulting in overall growth.",0.9591953158378601,0.019739383831620216,0.02106528729200363,positive,0.9394559264183044
39,2017-10-18 00:13:00,"The Zacks analyst believes that with expanding international operations, IDEXX's Companion Animal Diagnostics business is likely to suffer from adverse currency fluctuations in the third quarter.",0.03635820746421814,0.9378343224525452,0.025807470083236694,negative,-0.9014761447906494
40,2017-10-18 00:13:00,The Zacks analyst believes that improving throughput volume on higher refinery utilization will help Valero to generate more cash flow.,0.954757034778595,0.018148761242628098,0.02709420956671238,positive,0.9366082549095154
41,2017-10-18 00:13:00,The Zacks analyst believes TD Ameritrade is poised to growth through improving trading activities as DARTs continue to rise.,0.949958324432373,0.014803798869252205,0.0352378711104393,positive,0.9351544976234436
42,2017-10-18 00:13:00,"Moreover, increase in revenue and easing margin pressure is favorable.",0.9493990540504456,0.02029460296034813,0.030306318774819374,positive,0.9291044473648071
43,2017-10-18 00:13:00,"Per the Zacks analyst, weakness in the HCV franchise as a result of competitive and pricing pressure will impact Gilead's overall growth.",0.02047727070748806,0.9593960642814636,0.020126596093177795,negative,-0.9389187693595886
44,2017-10-18 00:13:00,The company will also lose exclusivity for HIV drug Viread.,0.017982646822929382,0.9203884601593018,0.061628907918930054,negative,-0.9024057984352112
45,2017-10-18 00:13:00,"Per the Zacks analyst, NGL business' weak performance forced Plains All American to lower its EBITDA outlook.",0.01726623997092247,0.9685035347938538,0.014230235479772091,negative,-0.9512373208999634
46,2017-10-18 00:13:00,Also it's facing rising competition as more companies are entering the midstream market.,0.7513567209243774,0.10604368895292282,0.14259955286979675,positive,0.645313024520874
47,2017-10-18 00:13:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
48,2017-10-18 00:13:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
49,2017-10-18 00:13:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
50,2017-10-18 00:13:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
